Skip to main content
MDAI logo

MDAI · Spectral AI, Inc.

Track MDAI — free
$1.60 +0.04 (+2.56%) At close · Sep 11
Market Cap
$51.50M
Shares
32.18M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.60 Open$1.57 Day$1.57–1.62 52W close$1.20–2.68 Avg vol 30d155K Short int2.2M · 6.9% float · 16.4d Short vol66% Last earningsAug 12, 2026 DataApr 2021–Sep 2026 Filing10-Q · Aug 11

Up next

Next earnings call
Dec 6, 2026 Est · unconfirmed · in 12 wks
filed Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$15.39M
Trailing 12 months
Net income (TTM)
−$10.09M
Trailing 12 months
Revenue growth YoY
-30.4%
Year over year
Operating margin
-77.2%
Trailing 12 months
P / E (TTM)
Trailing earnings
FCF yield
TTM · current market cap
Return on invested capital
Trailing 12 months
Net cash
$2.15M
Latest balance sheet
Dividend yield
Trailing 12 months
Shares change YoY
+26.2%
Year over year · more shares
Price change (1Y)
-19.6%
Trailing year
Short interest
6.9%
Latest settlement · 16.4 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Neutral Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.58
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −6%
below
Price vs 50-day avg −2%
below
RSI (14) 49
neutral
MACD trend Positive
52-week position 27%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Neutral
1-month return −8%
trailing
6-month return +4%
trailing
YTD return +13%
this year
Relative strength −14%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+14% holders QoQ · +12 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.94% of float · ▲ +6.2% MoM · 16.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
50 holders — near 3-yr high, broad support
Squeeze score 66
elevated · 0–100
Fundamentals
Excellent
Revenue growth −34%
Y/Y
Gross margin 45%
expanding
EPS growth +66%
Y/Y
Buyback $3.0M
authorized
Balance sheet $6.2M
net cash
Quant / Vol
risk profile
Very High
Volatility 70%
annualized · 1-yr
Max drawdown −55%
past year
ATR 4.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Aug 12, 2026
Revenue · year ending December 31, 2026 Initiated $18.5M
prior FY $19.65M midpoint −5.9% Y/Y

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 5 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−6% Bearish
Price vs 50-day avg
−2% Neutral
RSI (14)
49 Neutral
MACD trend
Positive Bullish
52-week position
27% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+14% holders QoQ · +12 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.94% of float · ▲ +6.2% MoM · 16.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
50 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $2 · 27% Range high $3
vs 200-day avg -6% vs 50-day avg -2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MDAI
Spectral AI, Inc.
this stock
$51.50M +12.7% -33.6% 6.9%
ABT
Abbott Laboratories
$177.58B -18.6% +5.7% 28.6 1.3%
MDT
Medtronic plc
$116.35B -5.3% +8.4% 22.4 0.9%
SYK
Stryker Corp
$105.70B -21.6% +11.2% 28.6 2.0%
BSX
Boston Scientific Corp
$62.29B -54.9% +12.5% 17.4 3.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
50
% held
21.3%
Net QoQ
+1.5M sh
Top holder
VANGUARD CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
11
View
Short & Settlement
Short Interest Rising
Shares short
2.2M
Days to cover
16.4d
Change
+131.3K sh
View
Short Volume
Short vol %
66%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
651
Value
$1.1K
As of
Aug 12, 2026
View
Off-Exchange
Off-exchange %
54.7%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$19.7M
Net income (FY)
$-7.6M
EPS diluted
$-0.29
View
Buybacks
Authorized
$3.0M
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 12, 2026
This year
15
View
Proposed Sales
Value
$1.8M
Shares
736.1K
Filed
Jul 21, 2025
View
Earnings & Events
Earnings Calls
Last call
Aug 12, 2026
View

Performance

5D 20D 120D MTD YTD
MDAI +2.6% -7.5% +3.9% +1.9% +12.7%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY +3.7% -5.8% -13.9% +2.3% +0.6%

Capital returns

Buyback program · as of Sep 30, 2024
Authorized
$3.00M
Spent (derived)
Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1833498 CUSIP 84757T105 13F (30d) 9 filings 9 filers Visit website Investor relations